Specific antagonists for glucose-depenent insulinotropic polypeptide (GIP)

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20080182795A1
SERIAL NO

12074462

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of treating non-insulin dependent diabetes mellitus in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP). In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BOSTON MEDICAL CENTERBOSTON MA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Neville, Linda Hull, MA 7 48
Tseng, Chi-Chuan Newton, MA 7 48
Wolfe, M Michael Newton, MA 23 142

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation